←Back to Expert Scholars
Translational Medicine / 转化医学RCC, VHL Disease
Eric Jonasch
MD
🏢MD Anderson Cancer Center🌐USA
Professor of Genitourinary Medical Oncology
80
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Eric Jonasch led pivotal trials of the HIF2 alpha inhibitor belzutifan in VHL associated tumors and advanced clear cell RCC. His work led to FDA approval of belzutifan for VHL disease. He directs the VHL program at MD Anderson and runs clinical trials in rare and hereditary kidney cancer.
Share:
🧪Research Fields 研究领域
RCC
VHL disease
belzutifan
HIF2 inhibitor
hereditary cancer
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Eric Jonasch 的研究动态
Follow Eric Jonasch's research updates
留下邮箱，当我们发布与 Eric Jonasch（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment